Recent content by Jurger

Of course every scientist that fails should just quit.

According to his Linkedin, Will McLean (on whose research FX-322 was founded on) left Frequency Therapeutics in April 2022 and is now Chief Scientific Officer at a new (unnamed) company. According to his profile, he is still working on regenerative medicine to restore hearing.

Great news.

There is absolutely no reason to assume that the reason FX-322 failed is because the supposed regenerated hair cells had no nerve endings. Hair cells without nerve endings result in hidden hearing loss. So you would expect a shift in audiogram results, but problems with hearing-in-noise for...

And if I might add: the hearing improvement must last long term. Some FX-322 patients lost their ‘gains’ after 1/2 years. Either the hair cell is there, or it isn’t there. Hearing loss drugs that need to be repeated yearly, hoping it will have the same effect as last time, is just ridiculous.

Yes but lab findings don’t always translate into real life findings. It would be interesting to study temporal bones of patients who participated in an FX-322 trial and got the drug. I think the lack of results has more to do with not regenerating (enough) hair cells than something that has gone...

We actually don’t, not in humans. We only know the drug gets in the cochlea (they did two studies on this with patients who were about to be implanted with a cochlear implant). My guess is the drug doesn’t stay in the cochlea long and deep enough to elicit a response. We know from studies on...

Fully agreed. I thought something was weird when they kept changing the goal posts after every trial. They already did that in 2019 when almost nothing showed up on the audiogram in the first Phase 1/2. And some people here did not want to have an honest debate about that.

Yes, sudden hearing loss/deafness happens all the time, but I do agree that judging from what we know of the efficacy of FX-322, he seems to be extremely responsive to it.

Interesting. I wonder when the gentleman participated in the trial. If it was one of the earlier ones, his recovery could be attributed to the natural healing that occurs over time in a lot patients with sudden deafness (particularly word recognition). Also, I wonder how much he recovered...

Mogrify and Astellas announce collaboration to conduct research on in vivo regenerative medicine approaches to address sensorineural hearing loss Cambridge, UK, Tokyo, Japan, 05 July 2022: Mogrify Limited (CEO: Darrin M. Disley, Ph.D., “Mogrify®”), a biopharmaceutical company transforming the...

Otoprotective drugs are interesting to me as a hearing loss patient, because they can provide insights with regards to getting drugs into the inner ear. One of my concerns is that intratympanic injections have significant drawbacks in terms of getting drugs deep and long enough in the cochlea to...

Looks to me as if PIPE-505 did not achieve the results they had hoped for.

Just watched this Fireside chat by Frequency Therapeutics: https://www.webcaster4.com/Player/Index?webcastId=45378&g=a6b36ac8-0c79-4079-ba1b-7631deefbbcd&uid=6671331&sid= An interesting moment was when Chris Loose was asked if FX-345 could leapfrog FX-322. He said it was “too early to...

It was a missed opportunity. The presenter asks the question at 25:45. Franck says ‘there’s a story there that kind of makes sense’ but he doesn’t actually explain it. Anyway, we’ll see how the 208 study unfolds. If it’s still the case 65% of patients don’t improve and those that do can lose...